About ImmunoVaccine (TSE:IMV)
Immunovaccine Inc., a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus. The company has research collaborations with companies and research organizations, including Merck KGaA, Incyte Corporation, and Leidos Inc, as well as with Zoetis. Immunovaccine Inc. was founded in 2000 and is based in Halifax, Canada.
Industry, Sector and Symbol
Trailing P/E Ratio-21.7777777777778
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
ImmunoVaccine (TSE:IMV) Frequently Asked Questions
What is ImmunoVaccine's stock symbol?
ImmunoVaccine trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."
When will ImmunoVaccine make its next earnings announcement?
Who are some of ImmunoVaccine's key competitors?
Some companies that are related to ImmunoVaccine include SIGA Technologies (SIGA), Sevion Therapeutics (SVON), Osiris Therapeutics (OSIR), VBI Vaccines (VBIV), NAPEC (NPC), XOMA (XOMA), ContraFect (CFRX), Anavex Life Sciences (AVXL), Medgenics (GNMX), Trillium Therapeutics (TRIL), Concordia International (CXR), Soligenix (SNGX), Windtree Therapeutics (WINT), Mateon Therapeutics (MATN), Affymax (AFFY), Tetralogic Pharmaceuticals (TLOG), Cubist Pharmaceuticals (CBST) and Idenix Pharmaceuticals (IDIX).
Who are ImmunoVaccine's key executives?
ImmunoVaccine's management team includes the folowing people:
- Andy Sheldon, Chairman of the Board
- Frederic Ors, Chief Executive Officer, Director (Age 42)
- Kimberly Stephens, Chief Financial Officer, Corporate Secretary
- Pierre Labbe CPA, Chief Financial Officer (Age 51)
- Joseph Sullivan, Senior Vice President - Business Development
- Gabriela Nicola Rosu, Chief Medical Officer
- Marc Mansour Ph.D., Director (Age 40)
- Albert James Scardino, Director (Age 66)
- Shermaine Tilley Ph.D., Director
- Wade K. Dawe, Independent Director
How do I buy ImmunoVaccine stock?
Shares of ImmunoVaccine and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is ImmunoVaccine's stock price today?
One share of ImmunoVaccine stock can currently be purchased for approximately C$1.91.
How big of a company is ImmunoVaccine?
ImmunoVaccine has a market capitalization of C$255.47 million.
How can I contact ImmunoVaccine?
ImmunoVaccine's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.
MarketBeat Community Rating for ImmunoVaccine (IMV)MarketBeat's community ratings are surveys of what our community members think about ImmunoVaccine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
ImmunoVaccine (TSE:IMV) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
ImmunoVaccine (TSE:IMV) Earnings History and Estimates Chart
ImmunoVaccine (TSE IMV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/29/2018|| || || || || || || || |
|8/9/2016||Q2 2016||C($0.02)||C($0.01)||C$0.10 million||C$0.07 million||View||N/A|
|5/10/2016||Q1 2016||C($0.02)||C($0.02)||C$0.10 million||C$0.07 million||View||N/A|
|3/29/2016||Q4 2015||C($0.02)||C$0.07 million||View||N/A|
|11/12/2015||Q3 2015||C($0.02)||C$0.07 million||View||N/A|
ImmunoVaccine (TSE:IMV) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ImmunoVaccine (TSE:IMV)
No dividend announcements for this company have been tracked by MarketBeat.com
ImmunoVaccine (TSE IMV) Insider Trading and Institutional Ownership History
ImmunoVaccine (TSE IMV) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
ImmunoVaccine (TSE IMV) News Headlines
|Immunovaccine to Host Investor Event on April 10, 2018 in New York City - GlobeNewswire (press release)|
globenewswire.com - March 15 at 3:20 PM
|Immunovaccine to Host Investor Event on April 10, 2018 in New York City|
finance.yahoo.com - March 14 at 6:38 AM
|Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies|
finance.yahoo.com - March 9 at 6:40 AM
|Fonds de solidarité FTQ Invests $5.75 Million In Immunovaccine Share Capital|
finance.yahoo.com - February 16 at 3:15 PM
|Immunovaccine Announces Closing of $14.375 million Bought Deal Offering with Over-allotment option exercised in full|
finance.yahoo.com - February 15 at 9:51 AM
|ImmunoVaccine Inc. (IMV) Director Buys C$30,080.00 in Stock|
www.americanbankingnews.com - February 13 at 6:46 PM
|Insider Buying: ImmunoVaccine Inc. (IMV) Insider Acquires 20,800 Shares of Stock|
www.americanbankingnews.com - February 13 at 12:30 PM
|Insider Buying: ImmunoVaccine Inc. (IMV) Director Purchases 10,000 Shares of Stock|
www.americanbankingnews.com - February 6 at 7:00 PM
|ImmunoVaccine Inc. (IMV) Director Purchases C$20,500.00 in Stock|
www.americanbankingnews.com - February 6 at 7:00 PM
|Insider Buying: ImmunoVaccine Inc. (IMV) Director Acquires 33,600 Shares of Stock|
www.americanbankingnews.com - January 26 at 12:26 PM
|Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020 - GlobeNewswire (press release)|
globenewswire.com - October 20 at 12:16 AM
|Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020|
finance.yahoo.com - October 18 at 2:33 AM
|Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Company’s DepoVax™-based Programs|
finance.yahoo.com - October 5 at 9:15 AM
|New Technology Could Help Detect The Leading Cause Of Strokes|
www.baystreet.ca - September 14 at 6:26 AM
|Daily Coverage on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International|
finance.yahoo.com - September 6 at 6:23 AM
|Immunovaccine Announces Achievement of Milestones in Collaboration with Zoetis to Develop Veterinary Vaccines|
finance.yahoo.com - August 31 at 7:52 PM
|Immunovaccine to Present at 19th Annual Rodman & Renshaw ... - Nasdaq|
www.nasdaq.com - August 31 at 6:14 AM
|Immunovaccine to Present at 19th Annual Rodman & Renshaw Global Investment Conference|
finance.yahoo.com - August 31 at 6:14 AM
|ImmunoVaccine, Inc. breached its 50 day moving average in a Bullish Manner : IMV-CA : August 9, 2017|
finance.yahoo.com - August 9 at 8:06 PM
|ImmunoVaccine Inc. (TSE:IMV) PT Set at C$2.50 by National Bank Financial|
www.americanbankingnews.com - August 9 at 3:58 PM
|Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017|
finance.yahoo.com - August 8 at 7:32 PM
|ImmunoVaccine, Inc. – Value Analysis (TORONTO:IMV) : July 31, 2017|
finance.yahoo.com - July 31 at 7:17 PM
|Insider Buying: ImmunoVaccine Inc. (TSE:IMV) Insider Buys 26,825 Shares of Stock|
www.americanbankingnews.com - July 31 at 1:25 PM
|Pierre Labbé Acquires 25,000 Shares of ImmunoVaccine Inc. (IMV) Stock|
www.americanbankingnews.com - July 21 at 1:19 PM
|ImmunoVaccine, Inc. breached its 50 day moving average in a Bullish Manner : IMV-CA : July 14, 2017|
finance.yahoo.com - July 15 at 2:51 AM
|Immunovaccine Achieves Breakthrough in Support of Developing Personalized Cancer Immunotherapies|
finance.yahoo.com - July 13 at 3:13 AM
|McCain: North Korea Is First ‘Real Test’ of Trump’s Presidency|
www.nbcnews.com - April 16 at 10:15 AM
|Syrian jets take off from air base hit by US|
abcnews.go.com - April 9 at 10:32 AM
|Fearless Florida diver pulls metal hook from shark's belly|
abcnews.go.com - March 25 at 10:38 PM
|Royal, Immunovaccine at 52-Week Highs|
www.baystreet.ca - February 6 at 5:59 PM
|Upbeat End To Quiet Week May Be In Store -- Canadian Commentary|
www.rttnews.com - February 3 at 6:27 PM
|Stocks Break Out Of Slumber Amid Jobs Momentum -- Canadian Commentary|
www.nasdaq.com - February 3 at 6:27 PM
|Appili Therapeutics Inc. Appoints Kimberly Stephens as Chief Financial Officer|
www.businesswire.com - October 3 at 5:21 PM
ImmunoVaccine (TSE:IMV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
ImmunoVaccine (TSE IMV) Stock Chart for Friday, March, 16, 2018